You are here

gene editing

A CRISPR alternative for editing genes without cutting

A CRISPR alternative for editing genes without cutting

Fierce Biotech

Columbia University

Flag link:

GSK partners with CRISPR pioneer Doudna to search for new drugs

GSK partners with CRISPR pioneer Doudna to search for new drugs

Stat

Flag link:

Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?

Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?

Motley Fool

Duchenne Muscular Dystrophy

Vertex Pharmaceuticals

CRISPR Therapeutics

Flag link:

Google Jumps Into Gene Editing: 5 Things You Need to Know

Google Jumps Into Gene Editing: 5 Things You Need to Know

Motley Fool

Verve Therapeutics

Flag link:

Research Roundup: New CRISPR, ALS, Colon Cancer, Asthma and More

Research Roundup: New CRISPR, ALS, Colon Cancer, Asthma and More

BioSpace

Flag link:

CRISPR edits out a deadly lung disease in mice before birth

CRISPR edits out a deadly lung disease in mice before birth

Fierce Biotech

Flag link:

First U.S. Patients Treated With CRISPR As Gene-Editing Human Trials Get Underway

First U.S. Patients Treated With CRISPR As Gene-Editing Human Trials Get Underway

NPR

Flag link:

AACR: After blood cancer successes, CAR-T treatments see inroads for solid cancers

AACR: After blood cancer successes, CAR-T treatments see inroads for solid cancers

Fierce Biotech

Flag link:

Living the CRISPR dream

Living the CRISPR dream

Pharmaforum

Caribou Biosciences

Flag link:

WHO panel pushes for genome editing research registry

WHO panel pushes for genome editing research registry

Fierce Biotech

Flag link:

Call For CRISPR Moratorium Echoes Early Days Of Gene Therapy

Call For CRISPR Moratorium Echoes Early Days Of Gene Therapy

Forbes

Flag link:

UC strengthens CRISPR IP position with new patent

UC strengthens CRISPR IP position with new patent

BioCentury

University of California

Flag link:

Gene-editing upstart lays out a $100M IPO with a plan to quickly leapfrog the leaders in their field

Gene-editing upstart lays out a $100M IPO with a plan to quickly leapfrog the leaders in their field

Endpoints

Precision Biosciences

Flag link:

Vaccines don’t work against some viruses. CRISPR might one day fix that

Vaccines don’t work against some viruses. CRISPR might one day fix that

Stat

Flag link:

CRISPR corrects DMD in mice for a year in Sarepta-supported study

CRISPR corrects DMD in mice for a year in Sarepta-supported study

Fierce Biotech

Duke University

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

World Health Organization Forms Committee To Guide Editing Of Human Genes

World Health Organization Forms Committee To Guide Editing Of Human Genes

NPR

Flag link:

Should Sangamo's Failure Make CRISPR Investors Nervous?

Should Sangamo's Failure Make CRISPR Investors Nervous?

Motley Fool

Sangamo Therapeutics

CRISPR Therapeutics

Editas Medicine

Flag link:

Sangamo Sinks Most in a Decade as Gene-Editing Study Fizzles

Sangamo Sinks Most in a Decade as Gene-Editing Study Fizzles

Bloomberg

Sangamo BioSciences

clinical trials

Flag link:

Vertex sharpens focus on gene-editing in licensing deal with Merck KGaA

Vertex sharpens focus on gene-editing in licensing deal with Merck KGaA

Endpoints

Vertex Pharmaceuticals

Flag link:

3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs

3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs

Motley Fool

Sarepta Therapeutics

Alzheimer's disease

Flag link:

Pages